Skip to main content
Erschienen in: International Journal of Hematology 5/2010

01.06.2010 | Original Article

Late effects in survivors of childhood acute lymphoblastic leukemia: a study from Thai Pediatric Oncology Group

verfasst von: Samart Pakakasama, Gavivann Veerakul, Darin Sosothikul, Su-on Chainansamit, Vichai Laosombat, Pattra Thanarattanakorn, Rachata Lumkul, Surapon Wiangnon, Somporn Wangruangsathit, Nattee Narkbunnam, Somjai Kanjanapongkul

Erschienen in: International Journal of Hematology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk of long-term late effects. Therefore, systematic screenings of the late complications are essential. The objective of this study was to determine the prevalence of late effects of Thai children and adolescents after completion of ALL therapy. We performed a cross-sectional study for evaluation of the late effects in ALL survivors who came for follow-up at 10 pediatric oncology centers in Thailand. We evaluated the treatment-related late complications of children and adolescents who had finished ALL treatment for at least 2 years. Demographic data, treatment modalities, and late effects were recorded and analyzed. There were 258 survivors with a median age of 12.2 years (range 3.6–23.3 years). The median follow-up time was 7.2 years (range 2–17.5 years). Forty-seven percent (122 cases) suffered from at least one late effect. Overweight/obesity was the most common late effect. Radiation of central nervous system was a significant risk factor for overweight/obesity (OR 1.97, 95% CI 1.02–3.81) and educational problems (OR 4.3, 95% CI 1.32–14.02). Our data have demonstrated a significant prevalence of late effects after childhood ALL therapy. A long-term follow-up program for survivors of childhood cancer is therefore needed in our country.
Literatur
2.
Zurück zum Zitat Haddy TB, Mosher RB, Reaman GH. Late effects in long-term survivors after treatment for childhood acute leukemia. Clin Pediatr. 2009;48:601–8.CrossRef Haddy TB, Mosher RB, Reaman GH. Late effects in long-term survivors after treatment for childhood acute leukemia. Clin Pediatr. 2009;48:601–8.CrossRef
3.
Zurück zum Zitat von der Weid N. Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study. Swiss Med Wkly. 2001;131:180–7.PubMed von der Weid N. Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study. Swiss Med Wkly. 2001;131:180–7.PubMed
4.
Zurück zum Zitat Bhatia S. Late effects among survivors of leukemia during childhood and adolescence. Blood Cell Mol Dis. 2003;31:84–92.CrossRef Bhatia S. Late effects among survivors of leukemia during childhood and adolescence. Blood Cell Mol Dis. 2003;31:84–92.CrossRef
5.
Zurück zum Zitat Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111:5515–23.CrossRefPubMed Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111:5515–23.CrossRefPubMed
6.
Zurück zum Zitat Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.CrossRefPubMed Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.CrossRefPubMed
7.
Zurück zum Zitat Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundation for providing risk-based health care for survivors. CA Cancer J Clin. 2004;54:208–36.CrossRefPubMed Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundation for providing risk-based health care for survivors. CA Cancer J Clin. 2004;54:208–36.CrossRefPubMed
8.
Zurück zum Zitat Wiangnon S, Kamsa-ard S, Jetsrisuparb A, et al. Childhood cancer in Thailand: 1995–1997. Asian Pacific J Cancer Prev. 2003;4:337–43. Wiangnon S, Kamsa-ard S, Jetsrisuparb A, et al. Childhood cancer in Thailand: 1995–1997. Asian Pacific J Cancer Prev. 2003;4:337–43.
9.
Zurück zum Zitat Laosombat V, Wongchanchailert M, Sattayasevana B, Wiriyasateinkul A, Watana-Arepornchai S. The treatment of children with acute lymphoblastic leukemia in Thailand. Med Pediatr Oncol. 2002;38:266–8.CrossRefPubMed Laosombat V, Wongchanchailert M, Sattayasevana B, Wiriyasateinkul A, Watana-Arepornchai S. The treatment of children with acute lymphoblastic leukemia in Thailand. Med Pediatr Oncol. 2002;38:266–8.CrossRefPubMed
10.
Zurück zum Zitat Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood. 2004;104:2690–6.CrossRefPubMed Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood. 2004;104:2690–6.CrossRefPubMed
11.
Zurück zum Zitat Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group late effects committee and nursing discipline. J Clin Oncol. 2004;22:4979–90.CrossRefPubMed Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group late effects committee and nursing discipline. J Clin Oncol. 2004;22:4979–90.CrossRefPubMed
12.
13.
Zurück zum Zitat Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005;45:881–91.CrossRefPubMed Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005;45:881–91.CrossRefPubMed
14.
Zurück zum Zitat Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Survivor Study. J Clin Oncol. 2003;21:1359–65.CrossRefPubMed Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Survivor Study. J Clin Oncol. 2003;21:1359–65.CrossRefPubMed
15.
Zurück zum Zitat Sklar CA, Mertens AC, Walter A, et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol. 2000;35:91–5.CrossRefPubMed Sklar CA, Mertens AC, Walter A, et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol. 2000;35:91–5.CrossRefPubMed
16.
Zurück zum Zitat Razzouk BI, Rose SR, Hongeng S, et al. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2007;25:1183–9.CrossRefPubMed Razzouk BI, Rose SR, Hongeng S, et al. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2007;25:1183–9.CrossRefPubMed
17.
Zurück zum Zitat Asner S, Ammann RA, Ozsahin H, Beck-Popovic M, von der Weid NX. Obesity in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:118–22.CrossRefPubMed Asner S, Ammann RA, Ozsahin H, Beck-Popovic M, von der Weid NX. Obesity in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:118–22.CrossRefPubMed
18.
Zurück zum Zitat Jaruratanasirikul S, Owasith K, Wongchanchailert M, Laosombat V, Sriplung H. Growth patterns and final height of survivors of childhood leukemia. J Pediatr Endocrinol Metab. 2004;17:719–26.PubMed Jaruratanasirikul S, Owasith K, Wongchanchailert M, Laosombat V, Sriplung H. Growth patterns and final height of survivors of childhood leukemia. J Pediatr Endocrinol Metab. 2004;17:719–26.PubMed
19.
Zurück zum Zitat Sklar C, Mertens A, Walter A, et al. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. J Pediatr. 1993;123:59–64.CrossRefPubMed Sklar C, Mertens A, Walter A, et al. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. J Pediatr. 1993;123:59–64.CrossRefPubMed
20.
Zurück zum Zitat Kurt BA, Armstrong GT, Cash DK, et al. Primary care management of the childhood cancer survivor. J Pediatr. 2008;152:458–66.CrossRefPubMed Kurt BA, Armstrong GT, Cash DK, et al. Primary care management of the childhood cancer survivor. J Pediatr. 2008;152:458–66.CrossRefPubMed
21.
Zurück zum Zitat Langer T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol. 2002;38:320–8.CrossRefPubMed Langer T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol. 2002;38:320–8.CrossRefPubMed
22.
Zurück zum Zitat Hudson MM. Survivors of childhood cancer: coming of age. Hematol Oncol Clin N Am. 2008;22:211–31.CrossRef Hudson MM. Survivors of childhood cancer: coming of age. Hematol Oncol Clin N Am. 2008;22:211–31.CrossRef
23.
Zurück zum Zitat Oeffinger KC, Nathan PC, Kremer LCM. Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Pediatr Clin N Am. 2008;55:251–73.CrossRef Oeffinger KC, Nathan PC, Kremer LCM. Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Pediatr Clin N Am. 2008;55:251–73.CrossRef
24.
Zurück zum Zitat Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640–9.CrossRefPubMed Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640–9.CrossRefPubMed
Metadaten
Titel
Late effects in survivors of childhood acute lymphoblastic leukemia: a study from Thai Pediatric Oncology Group
verfasst von
Samart Pakakasama
Gavivann Veerakul
Darin Sosothikul
Su-on Chainansamit
Vichai Laosombat
Pattra Thanarattanakorn
Rachata Lumkul
Surapon Wiangnon
Somporn Wangruangsathit
Nattee Narkbunnam
Somjai Kanjanapongkul
Publikationsdatum
01.06.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0594-9

Weitere Artikel der Ausgabe 5/2010

International Journal of Hematology 5/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.